Meglumine antimoniate

Meglumine antimoniate
Clinical data
Other names	Meglumine antimonate
AHFS/Drugs.com	Micromedex Detailed Consumer Information
ATC code	P01CB01 (WHO) QP51DX01 (WHO);
Identifiers
	IUPAC name Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol;
CAS Number	133-51-7 ;
PubChem CID	64953;
ChemSpider	58479 ;
UNII	75G4TW236W;
ChEMBL	ChEMBL239129 ;
NIAID ChemDB	008733;
CompTox Dashboard (EPA)	DTXSID4043935 ;
ECHA InfoCard	100.004.645
Chemical and physical data
Formula	Variable
Molar mass	Variable
3D model (JSmol)	Interactive image;
	SMILES O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO;
	InChI InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 ; Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M ;
	(what is this?) (verify)

Meglumine antimoniate is a medicine used to treat leishmaniasis.^[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.^[1] It is given by injection into a muscle or into the area infected.^[1]

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.^[1] It should not be used in people with significant heart, liver, or kidney problems.^[1] It is not recommended during breastfeeding.^[1] It belongs to a group of medications known as the pentavalent antimonials.^[1]

Meglumine antimoniate came into medical use in 1946.^[2] It is on the World Health Organization's List of Essential Medicines.^[3] It is available in Southern Europe and Latin America but not the United States.^[4]^[5]

Society and culture

It is manufactured by Aventis^[6] and sold as Glucantime in France, and Glucantim in Italy.

References

^ ^a ^b ^c ^d ^e ^f ^g World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 183. hdl:10665/44053. ISBN 9789241547659.
^ Sneader W (2005). "Chemical Medicines". Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ Wolfe M (2010). "Antiparasitic Drugs". In Bope ET, Kellerman RD, Rakel RE (eds.). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 978-1437735727. Archived from the original on 2016-12-20.
^ Gorbach SL, Bartlett JG, Blacklow NR (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.
^ "Sanofi-Aventis Bekräftigt Seine Verpflichtung Zur Sicherstellung Des Zugangs Zu Medikamenten in Den "Südlichen Ländern" Mit Einer Politik Der Gestaffelten Arzneimittelpreise Je Nach Bevölkerungseinkommen" [Sanofi-Aventis Reaffirms Its Commitment to Ensuring Access to Medicines in the "Southern Countries" With a Policy of Tiered Drug Prices Depending on Population Income]. Aventis press release (in German). 15 April 2005. Archived from the original on 22 May 2014.

[WHO2008-1] ^ ^a ^b ^c ^d ^e ^f ^g World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 183. hdl:10665/44053. ISBN 9789241547659.

[2] Sneader W (2005). "Chemical Medicines". Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.

[WHO21st-3] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[4] Wolfe M (2010). "Antiparasitic Drugs". In Bope ET, Kellerman RD, Rakel RE (eds.). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 978-1437735727. Archived from the original on 2016-12-20.

[5] Gorbach SL, Bartlett JG, Blacklow NR (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.

[6] "Sanofi-Aventis Bekräftigt Seine Verpflichtung Zur Sicherstellung Des Zugangs Zu Medikamenten in Den "Südlichen Ländern" Mit Einer Politik Der Gestaffelten Arzneimittelpreise Je Nach Bevölkerungseinkommen" [Sanofi-Aventis Reaffirms Its Commitment to Ensuring Access to Medicines in the "Southern Countries" With a Policy of Tiered Drug Prices Depending on Population Income]. Aventis press release (in German). 15 April 2005. Archived from the original on 22 May 2014.

[1]

[2]

[3]

[4]

[5]

[6]

Society and culture

See also

References